Bcl11b is a transcription factor important for T cell development and also a tumor-suppressor gene that is hemizygously inactivated in~10 % human T cell acute lymphoblastic leukemia (T-ALL) and several murine T-ALL models, including ATM −/− thymic lymphomas. Here we report that heterozygous loss of Bcl11b (Bcl11b +/− ) unexpectedly reduced lethal thymic lymphoma in ATM −/− mice by suppressing lymphoma progression, but not initiation. The suppression was associated with a T cell-mediated immune response in ATM −/− Bcl11b +/− mice, revealing a haploid insufficient function of Bcl11b in immune modulation against lymphoma and offering an explanation for the complex relationship between Bcl11b status with T-ALL prognosis.
Bcl11b is a transcription factor that is "monoallelically" inactivated in~10 % of human T cell acute lymphoblastic leukemia (T-ALL) [1] [2] [3] and several murine T-ALL models, including ATM −/− thymic lymphomas [4] [5] [6] . Both human and murine T-ALLs retain at least one intact copy of Bcl11b, indicating that Bcl11b is a bona fide haploinsufficient tumor-suppressor gene. Complete loss of the Bcl11b gene abrogates T cell development and gain of NK cell phenotype, revealing a critical role of Bcl11b in T cell lineage commitment [7] [8] [9] [10] . Conditional inactivation of both copies of Bcl11b in double-positive (DP) T cells leads to overproduction of innate CD8 + single-positive (SP) T cells [11] and compromises T-regulatory cell function [12] . Yet, hemizygous loss of Bcl11b has no measurable impact on T cell function [7] [8] [9] [10] and the mechanism by which it promotes T-ALL remains elusive.
To address this, we characterized Bcl11b +/− ATM −/− mice [6, 13] . ATM kinase is a master regulator of the DNA damage responses [14] . ATM −/− mice routinely succumb to immature T cell lymphomas sharing molecular features with human T-ALL. Of the ATM −/− thymic lymphomas, 80 % hemizygously deleted Bcl11b as a result of non-reciprocal t(12;14) translocation [6, 15] . Conditional inactivation of Bcl11b in T cells via LckCre eliminates recurrent t (12;14) translocations from ATM −/− thymic lymphomas, suggesting Bcl11b as the target of the large chromosome 12 deletion [16] . ATM −/− Bcl11b +/− mice were born at expected frequency (Additional file 1: Figure S1A ). Thymocyte development and peripheral T and B cell repertoire in young (4 week) ATM −/− Bcl11b +/− mice were indistinguishable from that of ATM −/− mice, displaying reduced surface TCRβ/CD3ε expression in DP cells and a partial blockade at the DP to SP transition characteristic for ATMdeficiency [6, 17] (Additional file 1: Figure S1B ).
While we initially expected Bcl11b-deficiency to accelerate ATM-deficient thymic lymphomas based on its frequent inactivation in T-ALLs, hemizygousdeletion of Bcl11b prevented lethal thymic lymphoma in~50 % ATM −/− mice and only 2/11 ATM −/− Bcl11b +/− mice developed overt thymic lymphomas (Fig. 1a ). The median survival of ATM −/− Bcl11b +/− mice was significantly longer than that of ATM −/− controls (167 vs. 106 days, p < 0.01) ( Fig. 1a ). Analyses of 3-and 10-monthold ATM −/− Bcl11b +/− mice revealed clonal expansion of immature (surfaceTCRβ low ) thymocytes in 3-month, but not 10-month-old ATM −/− Bcl11b +/− mice (Fig. 1b, c ). T cell lymphomas from 3-month-old ATM −/− Bcl11b +/− mice retained both WT and null alleles of Bcl11b, consistent with the lack-of-LOH in T-ALL ( Fig. 1d ). Despite the clonal Figure S1C ), suggesting that heterozygous Bcl11b-deficiency suppresses the progression, but not the initiation of ATM −/− thymic lymphomas.
Notably, almost all ATM −/− Bcl11b +/− mice developed variable degrees of splenomegaly, excessive submandibular lymph node (LN) enlargement that manifested to fatal airway obstruction (non-lymphoma-related death), and dermal inflammation commencing at 2-3 months of age ( Fig. 2a) . In contrast to normal lymphocyte profiles in 3month-old ATM +/+(+/−) Bcl11b +/− mice (Additional file 1: Figure S2A and S2B), histologic analyses consistently revealed a lymphocyte-mediated inflammatory/immune disorder in ATM −/− Bcl11b +/− mice characterized by marked plasmacytosis with reactive germinal centers (B220 + IgM + Bcl6 + CD138 − B cells) in submandibular LN, reactive follicular hyperplasia of the white pulp and increased extramedullary hematopoiesis in the red pulp in the spleen (Fig. 2b and Additional file 1: Figure S2C) , and acute and chronic dermal inflammation in the skin. While a cell-autonomous function of Bcl11b deletion on epidermal integrity cannot be ruled out [13] , the splenic and LN changes noted raised the possibility of an autoimmune disorder, which could have contributed to the lack of tumor progression in ATM −/− Bcl11b +/− mice. Correspondingly, 10-month tumor-free ATM −/− Bcl11b +/− mice accumulated activated CD8 + T cell in PB (Fig. 2c) .
Our data suggest that in an ATM-deficient background, heterozygous Bcl11b deficiency tilts immune homeostasis and limits the expansion, but not the initiation of ATM-deficient thymic lymphomas. Notably, homozygous Bcl11b deletion suppressed melanoma in murine models [18] . Given the role of Bcl11b in T cell lineage commitment, CD8 + T cell development, and Treg function, our data suggest that heterozygous Bcl11b deficiency can modulate anti-tumor immune response despite the lack of measurable T cell development defects in Bcl11b +/− mice [7] [8] [9] [10] . This role of Bcl11b in immune modulation and tumor suppression might explain the discrepancies between Bcl11b status (mutation, deletion, and downregulation) and T-ALL prognosis in different studies [1] [2] [3] 19] . It also suggests that Bcl11b is likely lost later during T-ALL development, as early deletion likely causes autoimmune dysfunction, analogous to TNFAIP3 (A20) in DLBCL [20] . Figure S2 . Analyses of autoimmunity in ATM −/− Bcl11b +/− mice. (A) Flow cytometric analysis of the spleen, bone marrow, and lymph nodes from 3-month and 10-month-old ATM −/− Bcl11b +/− mice. Notably, the frequency of the CD11b + myeloid cells increases in the spleen of ATM −/− Bcl11b +/− mice, consistent with increased extramedullary hematopoiesis in the red pulp seen in Fig. 2b. (B) Flow cytometric analyses of the thymus and spleen (SPL) from 3-month-old littermate ATM +/+ Bcl11b +/+ (WT), Bcl11b +/− , ATM +/− Bcl11b +/− mice. Double negative (DN) staining was performed on gated CD8-CD4-CD19-TCRγ/δ − thymocytes. Homozygous deletion of Bcl11b dramatically increased the number of phenotypical NK cells [8, 9] . The percentage of NK1.1 + or CD8 + cells does not significantly increase in the thymus and spleen of 3-month-old Bcl11b +/− mice. 
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